Why the study?
What are the aetiology and survival outcomes of patients presenting with malignant hypertension?
Population
83 patients presenting between 1979 and 1985 who fulfilled WHO criteria for malignant hypertension
Design
Cohort
Follow-up
up to 5 years
Authors
Loading...
Supports secondary cause evaluation in malignant hypertension; leaves open prospective validation of survival predictors.
What are the aetiology and survival outcomes of patients presenting with malignant hypertension?
In patients with malignant hypertension, secondary causes are more common (80%) than primary, and 5-year survival is approximately 75%, with initial serum creatinine serving as a prognostic indicator.
Yu et al. (1986) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: